Rezolute Shares Plummet Following Clinical Trial Failure

The stock of biotechnology firm Rezolute has collapsed in the wake of a disastrous outcome for its most promising drug candidate in a pivotal clinical study. This precipitous decline, which saw shares lose more than 79% of their value within a month, has now triggered legal scrutiny. Two law firms are investigating whether the company may have misled investors. In a contrasting move during the crisis, several of the company’s executives made significant share purchases.

Legal Scrutiny and Insider Purchases

In response to the severe losses sustained by shareholders, law firms Hagens Berman and Faruqi & Faruqi, LLP have now initiated formal investigations. They are examining whether Rezolute may have violated securities laws by making potentially misleading statements regarding the efficacy and commercial potential of its drug, Ersodetug, prior to the release of the trial data.

Amid this turmoil, multiple senior company officials opted to buy shares in the days following the crash. On December 15, CFO Daron Evans acquired 45,000 common shares for approximately $80,000. CEO Nevan C. Elam purchased 32,000 shares for about $51,000, while Chief Commercial Officer Sunil Ratilal Karnawat invested nearly $20,000 to obtain 12,100 shares. These transactions were executed at prices ranging from $1.59 to $1.79 per share.

The SunRIZE Trial Results That Sparked the Sell-Off

The massive downturn was set in motion on December 11 with the announcement of top-line results from the Phase 3 “sunRIZE” trial for Ersodetug. Developed to treat congenital hyperinsulinemia (HI), the medication failed to meet its primary endpoint. Although the highest dose reduced hypoglycemic events by approximately 45%, this result was not statistically significant because the placebo group also showed an improvement of around 40%. The drug also missed a key secondary goal.

Should investors sell immediately? Or is it worth buying Rezolute?

The market’s reaction was immediate and severe. On the day of the announcement, the equity plunged by as much as 90% intraday, closing at $1.40 after having traded at $10.94 the previous session. By December 17, the cumulative loss stood at 79.2%.

Analyst Community Downgrades Expectations

Following this significant setback, market analysts have substantially revised their assessments:

• Craig-Hallum downgraded the stock from “Buy” to “Hold,” slashing its price target from $18.00 to $2.00.
• While maintaining a “Buy” rating, Guggenheim reduced its target from $15.00 to $6.00.
• H.C. Wainwright and BTIG also kept their “Buy” recommendations but lowered their price objectives to $5.00, down from $14.00 and $17.00 respectively.

Path Forward: Shifting Focus to a Second Indication

Rezolute is conducting a comprehensive review of the trial data and plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the future of its HI program. Regardless of that outcome, the company is advancing Ersodetug for a separate condition: tumor-induced hyperinsulinemia. Topline results from the ongoing Phase 3 “upLIFT” study for this indication are anticipated in the second half of 2026. This trial follows a leaner development path and requires a smaller patient cohort, positioning it as a critical next milestone for the embattled firm.